HAVCR2 and non-small cell lung carcinoma: By integrating bioinformatics and computer-aided drug design methodologies, novel TIM-3-targeted inhibitors can be efficiently screened, optimized, and validated, potentially offering significant clinical benefits in NSCLC treatment (Zhang et al., 2025).